



ASX & Media Release

## Appointments to new Scientific Advisory Board

**Melbourne, Australia; December 13, 2016:** Patrys Limited (**ASX: PAB**) is pleased to announce that it has appointed two experienced US-based biotechnology executives, Dr Pamela M Klein and Dr Allen Ebens, to its newly convened Scientific Advisory Board (SAB).

Dr Pamela M Klein completed her medical training at Loyola University in Chicago before working at the U.S. National Cancer Institute. Dr Klein then moved to Genentech where, as Vice President, Development she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. After Genentech Dr Klein was appointed to the position of Chief Medical Officer of Intellikine where she built the clinical development capability and brought multiple early compounds from laboratory to clinic prior to Intellikine being acquired by Milleinium/Takeda. Dr Klein currently serves as an advisor to a range of different biotech and investment companies, with roles on Scientific Advisory Boards and Corporate Boards as well as broader advisory roles.

Dr Allen Ebens completed a PhD at UCLA and completed a Post-Doc at UCSF before joining Exelixis as a scientist in the Discovery Biology group. After more than 5 years with Exelixis Dr Ebens moved to Genentech where over 11 years in the Research Oncology group he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and cell-based therapies. Dr Ebens was recruited from Genentech to establish the oncology research lab at Juno Therapeutics, and he is currently the Senior Director, Immune Oncology at NGM Biopharmaceuticals in South San Francisco. Over a significant career Dr Ebens' contributions include advancement of 5 discovery projects to clinical development and leadership of T cell recruiting bi-specific antibody teams to proof of concept for multiple targets including one clinical candidate nomination.

“Patrys is delighted to have secured the services of two outstanding biotech experts for our SAB” said Dr James Campbell, Patrys’ CEO and Managing Director. “Between them Pamela and Allen have an incredible breadth of oncology development experience, ranging from basic biology through translation to clinical trials and regulatory prosecution. As Patrys progresses its development of Deoxymab 3E10 and other assets through pre-clinical testing and towards the clinic the team looks forward to the insight and guidance of the SAB”.

**For further information, please contact:**

*Patrys Limited:*  
James Campbell  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

*Patrys IR:*  
Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

*Patrys Media:*  
Kellie Stanborough  
Buchan Consulting  
P: +61 3 9866 4722  
[kstanborough@buchanwe.com.au](mailto:kstanborough@buchanwe.com.au)

Level 4, 100 Albert Road, South Melbourne, Victoria, 3205 Australia  
Phone: +61 (0) 3 96703273  
ABN: 97 123 055 363



**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).